It’s so wild that it just might work.
Get the latest international news and world events from around the world.
IgA Nephropathy in Adults
IgA nephropathy involves deposition of IgA-containing immune complexes in the glomerular mesangium, triggering glomerular inflammation and scarring.
IgA nephropathy is the most common cause of immune-mediated glomerular disease worldwide, with an estimated global incidence between 1.4 and 2.5 per 100 000 persons in the US.
Up to 50% of patients with IgA nephropathy develop kidney failure within 10 years of diagnosis, and life expectancy is estimated to be 6 years shorter for those with IgA nephropathy compared with matched controls.
📄 This Review summarizes the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy in adults.
This review discusses the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy (IgAN) in adults, with a focus on treatment recommendations based on the 2025 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for IgAN.
Why I Quit ChatGPT and Switched to Claude
“AI will most likely lead to the end of the world, but in the meantime there will be great companies created.” — Sam Altman, OpenAI CEO
I used to think that was dark humor.
This week, I stopped laughing — and cancelled my ChatGPT subscription.
Not because of the technology. Because of the values.
On February 27, Anthropic refused to give the Pentagon unrestricted access to its AI for mass surveillance and autonomous killer weapons. Within hours, OpenAI’s Sam Altman swooped in and took the deal.
One company held the line. The other sprinted to cross it.
Australian consortium to develop quantum biotechnology platform to transform Alzheimer’s treatment discovery
“Our system provides a pathway towards a fast, scalable tool for measuring real-time brain activity in synthetic tissue cultures that replicate human brain tissue,” Associate Professor Simpson said.
If successful, this brain-on-chip technology could help evaluate the effectiveness of treatments for neurological diseases, including Alzheimer’s, schizophrenia, epilepsy and anxiety, in the laboratory before moving into expensive and complex human trials.
Scientists just turned light into a remote control for crystals
NYU researchers have found a way to use light to control how microscopic particles assemble into crystals, effectively turning illumination into a tool for shaping matter. By adding light-sensitive molecules to a liquid filled with tiny particles, they can adjust how strongly the particles attract or repel one another simply by changing the light’s intensity or pattern. This allows them to trigger crystals to form, dissolve, or even be reshaped in real time.
‘An AlphaFold 4’ — scientists marvel at DeepMind drug spin-off’s exclusive new AI
Isomorphic Labs has developed a drug-protein interaction model which surpasses the previous tech in this area. Yet the model is proprietary, so no one knows how it was designed and trained and why it works so well!
Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left guessing how to achieve similar results.